Generated by AI
Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases. The company’s current pipeline centers on oral TYK2 inhibitors designed to address conditions such as plaque psoriasis and systemic lupus erythematosus, alongside a CNS-penetrant TYK2 program being studied for neuroinflammatory and neurodegenerative disorders. Alumis is also advancing lonigutamab, an antibody therapy aimed at thyroid eye disease, and additional discovery-stage programs built around its precision data analytics platform. The company works across immunology and inflammation, combining drug discovery, clinical development, and translational science to build treatments that may be used as monotherapy or in combination settings. Headquartered in South San Francisco, California, Alumis operates as a focused biotech platform in the autoimmune and immune dysfunction market.
Website280 East Grand Avenue
South San Francisco, CA, 94080
United States
The latest articles about ALMS.
Alumis now carries an updated fair value estimate of US$27.38, down from US$32.13, which reflects about a 15% reset in the price target. This change lines up with a split in recent analyst commentary after the LUMUS systemic lupus erythematosus study, with some focusing on execution risks and others pointing to potential in psoriasis and neurology. As you read on, you will see how this revised target fits into the broader, evolving Alumis story and how to track it over time. Stay updated as...
Summary of Sep 10's posts. Generated by AI.
Summary of Sep 2's posts. Generated by AI.
Summary of Sep 10's posts. Generated by AI.
Investors talking about ALMS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.